KALTF - Kalytera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0376
+0.0006 (+1.65%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0370
Open0.0287
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0287 - 0.0400
52 Week Range0.0248 - 0.1382
Volume83,818
Avg. Volume200,893
Market Cap17.187M
Beta (3Y Monthly)-0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

    Proceeds of the Private Placement will be used to fund preparatory work for initiation of the Company’s Phase 3 clinical registration study for its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Proceeds will also be used to augment the Company’s working capital as it continues discussions with potential corporate partners for its GVHD program.

  • GlobeNewswire

    Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) are significantly positive, and, as a result, the Company will not enroll the high dose cohort in its ongoing Phase 2 study, but will instead proceed directly to initiate a Phase 3 clinical registration study. The Company’s Phase 2 clinical study was designed in accordance with input received from the U.S. FDA.

  • GlobeNewswire

    Kalytera Announces Results of Shareholder Meeting Votes

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that shareholder votes on the election of directors, the approval of the Company’s auditors and the renewal of its Stock Option Plan were approved by the Company’s shareholders. The Company did not proceed with the shareholder vote with respect to the authorization of a potential share consolidation. Additional information regarding the Shareholder Meeting can be found in the Circular dated June 21, 2019, which was delivered to Kalytera shareholders and is available on the Company’s SEDAR profile.

  • GlobeNewswire

    Kalytera Will Not Proceed with Vote on Potential Share Consolidation

    Additional information regarding the Meeting can be found in the Circular dated June 21, 2019, which was delivered to Kalytera shareholders and is available on the Company’s SEDAR profile. Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics.

  • GlobeNewswire

    Kalytera Announces Completion of Food Effect and QTc Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is part of the Company’s product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Preliminary results for the Food Effect and QTc Study are positive and as expected.

  • GlobeNewswire

    Kalytera to Hold Annual and Special Meeting on July 29, 2019

    SAN FRANCISCO and TEL AVIV, Israel, July 05, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it is.

  • GlobeNewswire

    Kalytera to Acquire CBD Extraction Business

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has signed a Letter of Intent (“LOI”) to acquire a majority interest in Oregon 01, LLC (doing business as “Clean Bi Design”), which will operate a hemp-based cannabidiol (“CBD”) extraction facility in Amity, Oregon. Under the LOI, Kalytera has agreed to invest USD $3.5 million for the acquisition of a 51% interest in the business. The extraction facility will be both GMP certified and FDA compliant, and equipped with state-of-the-art equipment for extraction, distillation and isolation.

  • GlobeNewswire

    Kalytera Provides Update on GVHD Program

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). To date, the results of Kalytera’s Phase 2 clinical study have been positive and encouraging. No patients in the first (low dose) cohort developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and only one patient developed grade 2 acute GVHD.

  • GlobeNewswire

    Kalytera Announces Grant of Stock Options to Directors

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company.  The stock options have an exercise price of $0.05 per common share and expire ten years from the date of grant.  One third of the options granted will vest on June 19, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing July 2020. Stock options to purchase 68,698 common shares of Kalytera were granted to Ron Erickson, stock options to purchase 254,345 common shares were granted to Jeff Paley, and stock options to purchase 1,000,000 common shares were granted to Rob Hutchison, who very recently joined the Company’s board of directors.

  • GlobeNewswire

    Kalytera Announces Changes to Board of Directors

    Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by the resignation of Mr. Gary Leong, an independent director who also served on the Company’s Audit and Governance and Nominating Committees. Mr. Hutchison, who is an independent director, will also serve as a member of the Company’s Audit, Compensation and Governance and Nominating Committees.

  • GlobeNewswire

    Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation of the alpha3 glycine receptor shuts down pain transmission in inflammatory conditions, such as arthritis, colitis, and sciatica. “Today’s announcement is a milestone in Kalytera’s search for a breakthrough cannabinoid analgesic that will operate via a wholly new pathway,” stated Robert Farrell, Kalytera’s President and CEO.

  • GlobeNewswire

    Kalytera Reports First Quarter 2019 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2019. “Since the beginning of the year, we have made important progress in our lead product development program," stated Robert Farrell, Kalytera’s President and CEO. In the first quarter (“Q1”) of 2019, the Company recorded a net loss of approximately $6.4 million ($0.021 per Common Share), compared with a net loss of approximately $1.9 million ($0.01 per Common Share) in Q1 2018.

  • GlobeNewswire

    Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel compositions of cannabidiol (“CBD”) in combination with certain metabolites of the human microbiome as a potential treatment for ulcerative colitis, Crohn’s disease, inflammatory bowel disease (“IBD”), graft versus host disease (“GVHD”) and other GI tract inflammatory diseases.

  • GlobeNewswire

    Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced new laboratory findings demonstrating that cannabidiol (“CBD”) acts through a distinct biological pathway to restore epithelial cell tight junction integrity, which is highly important in preventing acute graft versus host disease (“GVHD”) and associated comorbidities. Acute GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. Prior to the bone marrow transplant, patients typically undergo a total body irradiation (“TBI”) procedure.

  • GlobeNewswire

    Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its cannabidiol ("CBD") therapeutic products for the prevention and treatment of graft versus host disease ("GVHD"), and to assist with the review of potential out-licensing opportunities for the commercial rights to these products. Kalytera has recently received unsolicited inquiries from companies interested in the rights to Kalytera’s GVHD products, and, in response to these inquiries, Kalytera’s board of directors approved the engagement of Echelon.

  • GlobeNewswire

    Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

    Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to announce the second closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross proceeds of CDN$1,617,500.

  • GlobeNewswire

    Kalytera Reports 2018 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year ended December 31 2018. Investors should note that the Company’s TSXV ticker symbol was recently changed from "KALY" to "KLY". For 2018, the Company recorded net income of approximately $6.9 million ($0.04 per Common Share), compared with a net loss of approximately $31.9 million ($0.26 per Common Share) in 2017.

  • GlobeNewswire

    Kalytera Therapeutics, Inc. Announces Closing of Public Offering

    Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANSISCO and TEL AVIV, Israel, April 26, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross proceeds of CDN$6,758,300.  Echelon Wealth Partners Inc. (“Echelon”) and Paradigm Capital Inc. (and together with Echelon, the “Agents”) acted as agents for and on behalf of the Company in connection with the Offering.

  • GlobeNewswire

    Kalytera Therapeutics Announces Filing of Short Form Prospectus

    Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (KALY.V) (KALTF) announced today that it has filed a final short form prospectus (the “Final Prospectus”) with securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario (and received a receipt therefor) in connection with its previously announced marketed offering of a minimum of 90,000,000 units of the Company (“Units”, or each a “Unit”) and a maximum of 200,000,000 Units for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). The first closing of the Offering is expected to occur on or about April 26, 2019, or such other date or dates as the Company and the Agents (as defined below) may agree (the “Closing Date”).

  • GlobeNewswire

    Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

    Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY and OTCQB: KALTF) announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario in connection with a proposed marketed offering of units of the Company (“Units”, or each a “Unit”) for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). Echelon Wealth Partners Inc. (the “Lead Agent”) and Paradigm Capital Inc. (collectively with the Lead Agent, the “Agents”) will conduct the Offering on a commercially reasonable efforts basis as the Company’s agents for the Offering in Canada.  The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state laws.

  • GlobeNewswire

    Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant.

  • GlobeNewswire

    Kalytera Announces Closing of Private Placement of Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce the closing of its previously announced non-brokered private placement (the “Offering”) under which it sold C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price).  The convertible debenture units consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature on March 6, 2021 (the “Maturity Date”).  The Company’s obligations under the Convertible Debentures will be guaranteed by its material subsidiaries, and such guarantee obligations will be secured by substantially all of the assets of such subsidiaries.

  • GlobeNewswire

    Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has initiated a food effect study (“Study KAL-07”), as part of its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Study KAL-07 is being initiated pursuant to written guidance received from U.S. Food and Drug Administration (the “FDA”).  The FDA is requiring that the Company complete a study in healthy volunteers to assess the effect of food intake on the absorption of oral CBD, prior to initiation of a Phase 3 registration study.

  • GlobeNewswire

    Kalytera Announces Private Placement of Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it is proceeding with a private placement (the “Offering”) under which it intends to sell C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price).  The convertible debenture units will consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature two years following the closing of the Offering (the “Maturity Date”).

  • GlobeNewswire

    Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group

    SAN FRANCISCO and TEL AVIV, Israel, Feb. 26, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the.